… Hence, underscoring the central role of P2Y12 inhibitors for … the need for more potent P2Y12
inhibitors. We then describe the … We try to rationalize the use of different P2Y12 inhibitors in …

… with ACS, adding P2Y12 inhibitors to aspirin and other … Among the commonly used
oral P2Y12 inhibitors, ticagrelor … is the usual initiating event in acute coronary syndrome (ACS). …

… inhibitor to reduce hard adverse events both at 30-day and 1-year follow-up. Antiplatelet
inhibition in acute coronary syndromes (… diphosphate receptor inhibitor has consistently reduced …

… available on oral P2Y 12 inhibitors in acute coronary syndrome. We aimed to evaluate …
safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-…

… downstream and upstream oral P2Y 12 inhibitors administration strategies in patients
with non–ST-segment elevation acute coronary syndrome undergoing invasive treatment. …

… inhibiting therapy using platelet function or genetic testing improves outcomes among patients
undergoing percutaneous coronary … -inhibiting therapy in acute coronary syndrome has …

… The aim of the present study was to establish the safety and efficacy profile of prasugrel
and ticagrelor in real-life acute coronary syndrome (ACS) patients with renal dysfunction. …

… inhibitor recommended for the standard treatment and secondary prevention of ischemic
events in acute coronary syndrome (… of more potent, newer P2Y 12 inhibitors. Prasugrel, a third-…

… of acute coronary syndromes (ACS). Currently, the guidelines recommend dual antiplatelet
therapy (DAPT) with aspirin and a potent P2Y 12 inhibitor (ie prasugrel or ticagrelor) for 12 …

… ticagrelor 8 has resulted in further improvements of the ischemic outcomes. Finally, clopidogrel
9 and ticagrelor… top of aspirin in patients with acute coronary syndromes, regardless of the …